中新社香港11月14日电 (记者 戴小橦)11月10日至14日当周，港股三大指数涨幅不一。截至14日收盘， 香港恒生指数累计涨1.26%，报26572.46点；恒生科技指数累计跌0.42%，报5812.80点；国企指数累计 涨1.41%，报9397.96点。 港股当周整体呈现"先升后回"的震荡格局，但细分板块表现亮眼。中国工商银行(亚洲)证券业务部分析 员叶泽恒向中新社记者表示，过去一周恒生生物科技指数涨超6%，显著跑赢大市。这一板块的强势表 现主要得益于三大支撑：一是美国大型医药生物企业并购活动升温，带动市场对相关企业的估值重估； 二是北半球冬季来临，流感病例增多推升药物及检测试剂需求；三是年内多家中国内地药企与国际知名 药厂达成合作，印证行业技术实力持续提升。 板块表现上，14日港股整体回调背景下，生物医药板块尽显韧性，逆势上涨。个股方面，旺山旺水涨幅 超20%，歌礼制药涨逾15%，圣诺医药、基石药业、来凯医药等涨幅均超10%。 港股生物医药板块逆势上涨 来源：中国新闻网 编辑：张澍楠 广告等商务合作，请点击这里 中新经纬版权所有，未经书面授权，任何单位及个人不得转载、摘编或以其它方式使用。 关注中新经纬 ...

Market Overview - US stock market decline impacts Hong Kong and A-shares, with Hang Seng Index closing down 1.85% [1] - October non-farm payroll report expected to be released, but will lack unemployment rate data, leading to incomplete labor market assessments [1] - Disagreement within the Federal Reserve regarding interest rate cuts, with December rate cut expectations dropping below 50% [1] Technology Sector - Japanese storage giant Kioxia reports a 60% drop in adjusted net profit for Q2, causing a collective decline in US storage stocks and affecting A-shares [3] - Despite strong Q3 results from Tencent, the stock did not perform well due to lower-than-expected capital expenditure guidance for 2025 [3] - Alibaba's entry into the C-end market against ChatGPT did not boost its stock, which fell over 4% [3] Energy Sector - National Energy Administration releases guidelines to promote the integration of renewable energy, focusing on green hydrogen and ammonia [4] - Shandong Province plans to promote over 2,000 hydrogen vehicles and build 38 hydrogen refueling stations [4] - Heavy increase in revenue for Reformed Energy in fuel cell systems, with overseas revenue surging 360% [4] Hydrogen Energy Developments - Guofu Hydrogen Energy's Qilu liquid hydrogen project successfully achieves 10 tons/day production, marking a significant technological advancement [5] - CIMC Group strengthens its position in the energy storage container market, with recent share buybacks leading to a stock increase of over 14% [5] Pharmaceutical Sector - Gilead Sciences announces clinical development of ASC36 and ASC35, with a projected FDA submission in Q2 2026, leading to a stock increase of over 15% [6] - Kingsray Biotech reports strong growth in CARVYKTI, with significant market demand and treatment center coverage expansion [6] Weather Impact on Energy Demand - Upcoming cold wave expected to increase heating demand, benefiting natural gas operators like China Gas and New Hope Energy [7] TCL Electronics Performance - TCL Electronics reports a 20.4% revenue growth in H1 2025, with significant increases in overseas sales and market share in AI/AR glasses [8][9] - The company’s global strategy and product optimization contribute to a 5.3% increase in global TV shipments [9]

Group 1 - A-shares demonstrate remarkable resilience amid a global market downturn, with the Shanghai Composite Index briefly turning positive and reaching a ten-year high, highlighting the unique attractiveness of the Chinese market [1] - The banking sector and regional stocks show strong performance, with major banks like ICBC and ABC hitting new highs [1] - The Hainan Free Trade Zone sector experiences significant gains, with stocks like Haima Automobile and Hainan Haiyao reaching their daily limit [1] Group 2 - The A-share market exhibits clear structural characteristics, with more stocks rising than falling; over 2800 stocks in Shanghai, Shenzhen, and Beijing are in the green, and the half-day trading volume reaches 1.25 trillion yuan [2] - The Shanghai Composite Index closes at 4022.89 points, down 0.16% [2] - The Shenzhen Component Index and the ChiNext Index both decline over 1% [3][4] Group 3 - The macroeconomic landscape shows a stable overall performance, with the People's Bank of China reporting a cumulative social financing increase of 30.9 trillion yuan in the first ten months of 2023, which is 3.83 trillion yuan more than the same period last year [10] - The year-on-year growth rate of social financing stock is 8.5%, while the broad money (M2) growth rate is 8.2%, both showing a slight decrease [10] - The National Bureau of Statistics indicates that despite investment growth slowing, the investment structure continues to optimize, suggesting significant future investment potential in China [11]

Market Overview - The Hong Kong stock market experienced a decline, with the Hang Seng Index falling 1.85% to 26,572.46 points, and the Hang Seng Technology Index dropping 2.82% to 5,812.8 points, amid a sell-off in US tech stocks and hawkish comments from multiple Federal Reserve officials [1] - The overall trading volume for the day was 232.79 billion HKD, with the Hang Seng Index showing a weekly increase of 1.26% [1] Blue-Chip Stocks Performance - JD Health (06618) led the blue-chip stocks with a 6.59% increase, closing at 68.75 HKD, contributing 7.49 points to the Hang Seng Index [2] - JD Health reported Q3 revenue of 17.12 billion RMB, a year-on-year increase of 28.7%, and operating profit of 1.243 billion RMB, up 125.3% [2] - Alibaba (09988) saw a decline of 4.38%, closing at 154.9 HKD, negatively impacting the Hang Seng Index by 107.48 points [2] Sector Performance - Major tech stocks faced pressure, with Alibaba down over 4% and Tencent down over 2% [3] - The cryptocurrency market also suffered, with Bitcoin dropping below 100,000 USD, and related stocks declining [3] - The healthcare sector saw a surge, with several stocks rising over 10%, while hydrogen energy stocks experienced significant gains, with Reshape Energy rising over 70% [3][4] Cryptocurrency Market - Bitcoin fell below 97,000 USD, with a 24-hour decline exceeding 6%, while Ethereum dropped nearly 10% [5] - The correlation between Bitcoin and the Nasdaq index remains high at 0.8, indicating a strong relationship with market sentiment [5] Pharmaceutical Sector Insights - The pharmaceutical industry is expected to see stable growth driven by innovation and supportive policies, with a focus on clinical value and market pricing [6] - Notable pharmaceutical stocks like 旺山旺水-B (02630) and 歌礼制药-B (01672) saw significant increases, with gains of 23.89% and 15.46% respectively [5][6] Hydrogen Energy Sector Developments - The National Energy Administration encourages the use of green hydrogen in coal chemical projects, with plans to promote hydrogen vehicles and establish hydrogen refueling stations [7] - The hydrogen energy sector is anticipated to benefit from supportive policies and market expansion, with companies like Reshape Energy seeing substantial stock price increases [7] Notable Stock Movements - 中集集团 (02039) surged 14.17% to 8.3 HKD, driven by its competitive edge in the energy storage sector [8] - 派格生物医药-B (02565) reached a new high, increasing 12.15% to 63.25 HKD following the approval of its new drug application [9] - 基石药业-B (02616) rose 10.75% to 6.08 HKD, supported by a significant share increase from the Government of Singapore Investment Corporation [10] - 伟易达 (00303) fell 12.11% to 58.8 HKD after reporting a revenue decline of 9.05% for the half-year period [11]

Market Performance - The Hang Seng Index increased by 1.26% this week, closing at 26,572.46 points, while the Tech Index decreased by 0.42% to 5,812.80 points, and the National Enterprises Index rose by 1.41% to 9,397.96 points [2][4]. Market Dynamics - The fluctuations in the Hong Kong stock market are closely related to external environments, particularly the impact of the U.S. government shutdown, which temporarily locked nearly one trillion dollars in liquidity, raising the cost of dollar funds and pressuring risk assets like U.S. and Hong Kong stocks [4]. - A recent report from Western Securities suggests that the end of the U.S. government shutdown may release previously "frozen" dollar liquidity, potentially leading to a liquidity-driven rally in the Hong Kong stock market [4]. Capital Inflows - Southbound capital has provided strong support, with net purchases through the Stock Connect exceeding HKD 1.3 trillion this year, totaling over HKD 5 trillion, indicating a shift towards a "semi-onshore market" where domestic capital plays a more significant role in pricing [4]. Sector Performance - Pharmaceutical stocks have seen renewed interest, with notable gains: - Gilead Sciences (01672.HK) up 45.40% - Clover Biopharmaceuticals (02197.HK) up 29.95% - Yummy (02589.HK) up 18.81% - The positive performance is attributed to strong Q3 results in innovative drugs and life sciences sectors [5]. - Other notable performers include: - HuShang Ayi (02589.HK) up 31.44% due to a new ten-year H-share incentive plan and reaching over 10,739 stores [5]. - Lee & Man Paper (00746.HK) up 17.37% benefiting from rising paper prices [5]. - Conversely, companies like Sanhua Intelligent Control (02050.HK) and Legend Holdings (06683.HK) faced declines of 10.93% and 19.82%, respectively, due to market risk aversion and concerns over equity dilution from a recent share placement [5]. Gold and Automotive Sectors - Gold stocks weakened following hawkish comments from Federal Reserve officials, with China Gold International (02099.HK) down 3.94% and Zijin Mining (02899.HK) down 2.94% [6][7]. - The automotive sector also faced declines, with Xpeng Motors (09868.HK) down 6.80% amid a drop in retail sales of passenger cars by 19% year-on-year for the first nine days of November [10][11]. Brokerage and Semiconductor Stocks - Chinese brokerage stocks adjusted, with major firms like GF Securities (01776.HK) and China Galaxy (06881.HK) experiencing declines due to a significant drop in new account openings [13]. - Semiconductor stocks also fell, influenced by a broader sell-off in U.S. tech stocks, with Shanghai Fudan (01385.HK) down 5.92% and SMIC (00981.HK) down 2.78% [14][16]. Individual Stock Movements - Lehua Entertainment (02306.HK) rose nearly 8% amid speculation regarding a contract renewal with a prominent artist [18]. - Zhonghui Biopharmaceuticals (02627.HK) increased by over 6% after announcing the initiation of Phase I clinical trials for its flu vaccines [19].

Market Overview - The Hong Kong stock market experienced a decline today, with the Hang Seng Index closing at 26,572.46 points, down 500.57 points, representing a drop of 1.85% [2] - The Hang Seng Technology Index also fell, closing at 5,812.80 points, down 168.50 points, a decrease of 2.82% [5] Sector Performance - Technology stocks faced widespread declines, with Baidu Group-SW (09888.HK) dropping over 7%, JD Group-SW (09618.HK) down over 6%, and Alibaba-W (09988.HK) falling over 4% [5] - The lithium battery sector saw significant losses, with Tianqi Lithium (09696.HK) down over 4% and Ganfeng Lithium (01772.HK) down over 3% [5] - Chinese brokerage stocks weakened, with CITIC Securities (06030.HK) declining over 4% [5] - Conversely, the innovative drug sector saw gains, with Gilead Sciences-B (01672.HK) rising over 15%. The innovative drug sector reported a 36% year-on-year revenue growth in Q3, with continued quarter-on-quarter growth [5] Capital Flow - After a small net sell-off of southbound funds yesterday, there was a return of capital today, with a cumulative net purchase of Hong Kong stocks reaching 12.8 billion HKD by the end of the trading day [6] Future Outlook - Western Securities noted that the reopening of the U.S. government and the return of liquidity from the Federal Reserve could lead to a significant reversal of previous pessimistic trading assumptions. This may provide a larger rebound space for risk assets that had previously declined due to tightened liquidity [8] - The report suggests that the Hong Kong market, particularly the Hang Seng Technology Index, may benefit from this shift in liquidity, potentially leading to a strong rebound [8] - The current effective investment strategy is to maintain a positive yet cautious approach, focusing on balanced allocation and avoiding chasing high prices, while being vigilant about external factors such as U.S. Federal Reserve policies and U.S.-China relations [8]

Market Overview - The Asia-Pacific stock markets showed a collective decline influenced by the overnight drop in US stocks, with the Hang Seng Index falling below the 27,000-point mark [1] - On November 14, the three major indices in Hong Kong all fell, with the Hang Seng Technology Index down 2.82%, the Hang Seng Index down 1.85%, and the National Enterprises Index down 2.09% [1] Stock Performance - Major technology stocks experienced significant declines, with Baidu down over 7%, JD.com down over 6%, and Alibaba down over 4% [4][5] - The film and entertainment sector led the declines, with DaMai Entertainment dropping over 10% [6] - Cryptocurrency-related stocks also fell sharply, coinciding with Bitcoin dropping below $97,000, marking a new low since May 8 [7] Sector Performance - The banking, insurance, and Chinese brokerage stocks were sluggish, with CITIC Securities, GF Securities, and China Galaxy all down over 4% [8][9] - Conversely, the biopharmaceutical sector saw gains, with Gilead Sciences rising over 15% and other pharmaceutical stocks also performing well [10][11] Notable Stocks - The pork concept stocks were active, with WH Group rising 1.64%, supported by favorable market outlooks for pork prices in the US and China [12] - Southbound capital saw a net inflow of HKD 12.887 billion, indicating continued interest in Hong Kong stocks [13] Market Outlook - According to GF Securities, the foundation of the Hong Kong bull market remains intact, but the evolution is expected to be characterized by "oscillating upward" rather than rapid increases, emphasizing the importance of high-prosperity sectors [15]

Core Viewpoint - The Asia-Pacific stock markets experienced a collective downturn influenced by a significant drop in the US stock market, with major indices in Hong Kong falling sharply [1] Group 1: Market Performance - The Hang Seng Technology Index plummeted by 3.1% at one point, ultimately closing down 2.83% [1] - The Hang Seng Index and the China Enterprises Index declined by 1.85% and 2.09%, respectively, with the Hang Seng Index losing 500 points and falling below the 27,000 mark [1] Group 2: Sector Performance - Major sectors such as large technology stocks, financials (including banks, insurance, and brokerages), and state-owned enterprises contributed to the market decline [1] - Baidu's stock dropped over 7% following its earnings report, while CITIC Securities fell more than 5%, China Life Insurance declined nearly 3%, and Agricultural Bank of China decreased by nearly 2% [1] - Bitcoin fell below $97,000, leading to a broader decline in cryptocurrency-related stocks, while semiconductor, automotive, photovoltaic, aviation, military, and precious metal stocks also experienced losses [1] Group 3: Resilient Sectors - Conversely, the biopharmaceutical sector saw gains, with Gilead Sciences rising over 15%, and both Lai Kai Pharmaceutical and Saint Noble Pharmaceutical increasing by over 12% [1] - JD Health led the internet healthcare stocks with a rise of over 6% [1] - Citigroup noted favorable prospects for pork prices in the China-US market, contributing to a historical high for the leading pork stock, WH Group [1]

Group 1 - The core viewpoint of the articles highlights the strong performance of innovative drug stocks in the market, with notable increases in share prices for companies such as Gilead Sciences-B (up 8.82%) and Kintor Pharmaceutical (up 4.60%) [1] - The report from CICC emphasizes the importance of innovative drugs and medical devices in China's "14th Five-Year Plan," indicating a shift from "follow-up innovation" to "quality transformation" in domestic innovative drugs [1] - The collaboration between Hansoh Pharmaceutical and Roche for the global exclusive license of the antibody-drug conjugate HS-20110 is seen as a significant advancement, with expectations for smooth development due to Roche's expertise [2] Group 2 - The partnership between Innovent Biologics and Takeda Pharmaceutical aims to advance the development of next-generation tumor immunotherapy and antibody-drug conjugates, leveraging Takeda's strong sales network in Japan and the West [2] - Valiant Pharmaceuticals' agreement with the U.S. company Dianthus for the development and commercialization of its autoimmune drug LBL-047 outside Greater China is viewed as beneficial for product development [2] - The overall sentiment in the pharmaceutical industry is optimistic regarding the international expansion of innovative drugs, with multiple companies securing significant partnerships to enhance their research and commercialization efforts [2]

受隔夜美股大跌影响，港股上午盘三大指数齐挫，恒生科技指数跌幅较大，午间收跌2.2%，恒生指数 跌1.26%再度失守27000点，国企指数跌1.38%。作为市场风向标的权重科技股集体走低大市承压明显， 尤其是百度绩后大跌超7%表现较弱，京东、阿里巴巴等齐跌；昨日强势的铝、铜等有色金属股走低， 中资券商股、苹果概念股、汽车股、保险股纷纷下跌。另外，药品类股走势活跃，互联网医疗股方向涨 幅明显，歌礼制药大涨近15%领衔创新药上涨。(格隆汇) ...